Navigation Links
Moores UCSD Cancer Center studying novel leukemia vaccine for high-risk patients

Researchers at the Moores Cancer Center at the University of California, San Diego (UCSD) are conducting clinical trials of a novel therapy aimed at revving up the immune system to combat a particularly difficult-to-treat form of leukemia.

The experimental therapy is being offered to patients with chronic lymphocytic leukemia (CLL) whose cancer did not respond or was resistant to initial treatment or harbors a particular chromosomal abnormality called a 17p deletion. In most of these cases, the cancer has failed to respond to further conventional therapy.

In this clinical trial, patients will receive a vaccine of an immune-boosting molecule, ISF35 (Immune Stimulatory Factor 35) followed by three courses of rituximab, a monoclonal antibody, and the chemotherapy drugs fludarabine and cyclophosphamide (FCR). The trial is termed Phase I, meaning that it is aimed at testing the safety of the combination of repeat infusions of ISF35 and FCR, the latter being considered the standard and best possible CLL treatment.

"This approach activating immune cells followed by chemotherapy may lead to new strategies that could be applied to other cancers," said Januario E. Castro, M.D., assistant clinical professor of medicine at the UC San Diego School of Medicine and the Moores UCSD Cancer Center, who leads the work. The vaccine therapy approach makes it possible to target the cancer cells and activate the immune system by making the cancerous leukemia B cells more visible. The activated immune system can then find and eliminate the cancer cells.

CLL can be especially hard to treat. Though chemotherapy can beat back the disease initially, and patients may do well for years, the disease invariably returns, frequently resistant to further treatment. The American Cancer Society estimates that about 15,100 new cases of CLL will occur this year in the United States, with about 4,390 deaths from the disease.

"Standard strategies for CLL involve drugs and drug combinations that result in serious toxicities, little or no improvement in survival, and poor tolerance by the elderly," Castro said. "Almost all patients eventually experience disease relapse and become less responsive to therapy. Clearly we need novel therapeutic approaches for CLL, and ISF35 therapy represents such an innovation."

According to Castro, the latest study builds on previous trials completed at UCSD and M.D. Anderson Cancer Center in Houston. "Those trials showed remarkable results for ISF35 in patients with high-risk and treatment-resistant CLL," he said, particularly when combined with chemotherapy.

Castro said that ISF35 also has the "potential to treat a range of blood cancers including lymphomas and even certain types of breast and lung cancers and melanoma," adding that future clinical trials are being planned.


Contact: Steve Benowitz
University of California - San Diego

Related medicine news :

1. Novel Lung Cancer Vaccine Trial Launched at Moores UCSD Cancer Center
2. Zounds Hearing Enters Moorestown and Announces $225,000 Hearing Partnership With Twilight Wish Foundation
3. Tackling a hard-to-treat childhood cancer by targeting epigenetic changes
4. HPV virus helps cervical and head and neck cancers resist treatment and grow and spread
5. New research finds markers for esophageal cancer before it develops
6. Tackling Hard-to-treat Childhood Cancer by Targeting Epigenetic Changes
7. Samsung and Susan G. Komen for the Cure(R) Launch Historic Breast Cancer Alliance
8. Join the Pancreatic Cancer Action Network and Raise Your Voice in November for Pancreatic Cancer Awareness Month
9. Cancer Patients in Southeastern Florida Now Benefiting From RapidArc(TM) Radiotherapy Treatments
10. Substance tackles skin cancer from 2 sides
11. Excess Weight Seems to Boost Breast Cancer Risk
Post Your Comments:
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance ... care insurance companies have a waiver for care if the client has a cognitive ... the family pays for care, is often waived, so the benefits from their insurance ...
(Date:10/13/2017)... ... ... Talented host, actor Rob Lowe, is introducing a segment ... of "Success Files," which is an award-winning educational program broadcasted on PBS Member ... with passion and integrity. , Sciatica occurs when the sciatic nerve in the ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... are now treating sleep apnea using cutting-edge Oventus O2Vent technology. As ... serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, ... post-acute health care, have expanded their existing home health joint venture through an ... has been operating a joint venture home health company with Asante, delivering clinically ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the Health & ... by Moonlight to raise money for the American Heart Association Heart Walk. Teams of ... will work together to keep their treadmills moving for 5 hours. Treadmills will start ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... FRISCO, Texas , Oct. 11, 2017 /PRNewswire/ ... healthcare services, has amplified its effort during National ... patients about hereditary cancer risks. ... Journal of Clinical Oncology calculated that more than ... to have inherited mutations in BRCA1 or BRCA2 and ...
(Date:10/10/2017)... , Oct. 10, 2017  NDS received FDA 510(k) clearance ... a medical-grade battery-powered display stand specifically designed for endoscopy environments. An ... technology into a clinical solution to support the improvement of patient ... Innovative Design ... Wireless Solution ...
(Date:10/7/2017)...   Provista, a proven leader in the ... purchasing power, today announced a new resource area on ... is the online home for case studies, articles ... news releases, slideshows and events. ... resources at their fingertips, viewers can also watch short ...
Breaking Medicine Technology: